Skip to content
No picture yet

Mekinist 2 mg – DIN 02409658

Mekinist is Trametinib 2 mg (tablet), sold in Canada. It is used for lung cancer and melanoma. It is supplied by Novartis Pharmaceuticals Canada Inc. We don't have a photo or description of what this pill looks like yet, so check the name and code on the box or bottle, and ask a pharmacist before taking it. Its official Health Canada listing links to the product monograph, which describes the tablets.

Sold in Canada

Trametinib 2 mg

Brand
Mekinist
Strength
2 mg
Used for
Lung cancer and melanoma
Form
Tablet
Manufacturer
Novartis Pharmaceuticals Canada Inc
Drug class
Cancer medicine (kinase inhibitor)
Sold in
Canada
DIN
02409658

Source: Health Canada's Drug Product Database. Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Trametinib pills and guides

What is Trametinib used for?

Trametinib is used for lung cancer and melanoma.

Medicine type
Cancer medicine (kinase inhibitor)
Official uses from the US prescribing label

BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma

MEKINIST® is indicated, as a single agent in BRAF-inhibitor treatment-naïve patients or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.

Adjuvant Treatment of BRAF V600E or V600K Mutation-Positive Melanoma

MEKINIST is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.

BRAF V600E Mutation-Positive Metastatic NSCLC

MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.

BRAF V600E Mutation-Positive Locally Advanced or Metastatic Anaplastic Thyroid Cancer

MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options.

BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

MEKINIST is indicated, in combination with dabrafenib, for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

BRAF V600E Mutation-Positive Low-Grade Glioma

MEKINIST is indicated, in combination with dabrafenib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.

Limitations of Use

MEKINIST is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition.

From the FDA-approved label on DailyMed (published May 20, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your medicine? Check the box

  • The box or bottle shows DIN 02409658.
  • It names Mekinist, Trametinib 2 mg.
  • A loose pill is a different matter: without a description of its markings, a pharmacist has to confirm what it is.

Sold in Canada as Mekinist by Novartis Pharmaceuticals Canada Inc.

In Canada: prescription only.

Ingredients

Active: Trametinib

Other Trametinib pills